

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Ho Carole</u> (Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. (Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Denali Therapeutics Inc. [DNLI]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Medical Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/02/2019</u>	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock							46,875	D ⁽¹⁾		
Common Stock							25,000	I	See footnote ⁽²⁾	
Common Stock	01/02/2019		M		5,775	A	\$5.28	183,900	I	See footnote ⁽³⁾
Common Stock	01/02/2019		S ⁽⁴⁾		4,875	D	\$19.43 ⁽⁵⁾	179,025	I	See footnote ⁽³⁾
Common Stock	01/02/2019		S ⁽⁴⁾		900	D	\$20.24 ⁽⁶⁾	178,125	I	See footnote ⁽³⁾
Common Stock	01/03/2019		M		5,775	A	\$5.28	183,900	I	See footnote ⁽³⁾
Common Stock	01/03/2019		S ⁽⁴⁾		5,775	D	\$18.9 ⁽⁷⁾	178,125	I	See footnote ⁽³⁾
Common Stock	01/04/2019		M		5,950	A	\$5.28	184,075	I	See footnote ⁽³⁾
Common Stock	01/04/2019		S ⁽⁴⁾		1,500	D	\$19.3 ⁽⁸⁾	182,575	I	See footnote ⁽³⁾
Common Stock	01/04/2019		S ⁽⁴⁾		4,450	D	\$20.03 ⁽⁹⁾	178,125	I	See footnote ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (right to buy)	\$5.28	01/02/2019		M		5,775		(10)	07/01/2026	Common Stock	5,775	\$0.00	78,600	D	
Stock Option (right to buy)	\$5.28	01/03/2019		M		5,775		(10)	07/01/2026	Common Stock	5,775	\$0.00	72,825	D	
Stock Option (right to buy)	\$5.28	01/04/2019		M		5,950		(10)	07/01/2026	Common Stock	5,950	\$0.00	66,875	D	

Explanation of Responses:

1. The shares are held of record by Carole Ho and Rajat Rohatgi.
2. Shares held of record by The Rohatgi-Ho Irrevocable GST Trust.
3. The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
4. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
5. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$19.11 to \$20.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
6. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$20.13 to \$20.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
7. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$18.56 to \$19.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
8. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$18.77 to \$19.76 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
9. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$19.81 to \$20.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
10. Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter.

Remarks:

This Form 4/A is being filed in order to correct an omission in the shares exercised and sold by the Reporting Person as reported on the original Form 4 filed on January 4, 2019.

/s/ Tyler Nielsen, by power of attorney 11/30/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.